Rosen Law Firm Advises AstraZeneca Investors on Class Action Deadline

NEW YORK, Feb. 09, 2025 (GLOBE NEWSWIRE) --

WHY: The Rosen Law Firm, an international law firm focused on investor rights, is reminding individuals who bought securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022, and December 17, 2024 (the "Class Period"), about the upcoming February 21, 2025, lead plaintiff deadline in a securities class action initially filed by the firm.

SO WHAT: If you purchased AstraZeneca securities during the Class Period, you might be eligible for compensation without needing to pay out-of-pocket fees through a contingency fee arrangement.

WHAT TO DO NEXT: To become a part of the AstraZeneca class action, you can visit this link or contact Phillip Kim, Esq., toll-free at 866-767-3653, or via email at [email protected] for further information regarding the class action. A lawsuit has already been filed, and if you would like to take on the role of lead plaintiff, you must file your motion with the court by February 21, 2025. A lead plaintiff is a representative acting on behalf of other class members to guide the litigation.

WHY CHOOSE ROSEN LAW: Investors should consider selecting skilled legal counsel with proven experience in significant roles. Many firms that send out notifications lack the same level of experience, resources, or peer recognition. Often, these firms do not actually handle securities class actions but instead refer clients to firms that do. It is important to make an informed choice when picking your legal representation. The Rosen Law Firm advocates for investors globally, focusing on securities class actions and shareholder derivative litigation. The firm has set records, including achieving the largest securities class action settlement involving a Chinese company at the time. In 2017, the firm was rated No. 1 by ISS Securities Class Action Services for the number of securities class action settlements. It has consistently ranked among the top four firms since 2013 and has recovered hundreds of millions for investors; for example, in 2019, the firm obtained over $438 million for its clients. Additionally, in 2020, founding partner Laurence Rosen was recognized as a Titan of the Plaintiffs' Bar by Law360, while many of the firm’s lawyers have also received accolades from Lawdragon and Super Lawyers.

CASE DETAILS: The lawsuit alleges that throughout the Class Period, defendants made materially false and misleading statements or failed to disclose: (1) AstraZeneca was involved in insurance fraud in China; (2) this led to increased legal risks for AstraZeneca in China, ultimately resulting in the detention of the President of AstraZeneca China by local authorities; (3) the company understated its legal risks; (4) this situation, once made public, could significantly harm AstraZeneca’s business in China; and (5) the defendants’ claims regarding AstraZeneca's business and prospects were misleading at all relevant times. When the actual information became known, the lawsuit asserts that investors sustained losses.

If you wish to join the AstraZeneca class action, please go to this link, call Phillip Kim, Esq. at 866-767-3653, or email [email protected] for more information.

No Class Has Been Certified. Until a class is officially certified, you are not represented by legal counsel unless you hire one. You may choose any lawyer you prefer. Alternatively, you can remain a passive class member and take no action at this point. An investor's ability to receive a portion of any potential recovery does not depend on serving as lead plaintiff.

For updates, follow us on LinkedIn: LinkedIn or on Twitter: Twitter or on Facebook: Facebook.

This article is considered attorney advertising. Past outcomes do not assure future success.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40^th Floor

New York, NY 10016

Phone: (212) 686-1060

Toll-Free: (866) 767-3653

Fax: (212) 202-3827

Email: [email protected]

Website: www.rosenlegal.com

AstraZeneca, lawsuit, investors